Miroslaw Lech

Miroslaw Lech is a Principal Scientist at Parabilis Medicines since December 2018, with a focus on Discovery Proteomics, and also serves as a Consultant at Spectrus LLC, where work involves mass spectrometry-based proteomics and enhancing analytical methods. Previously, at Momenta Pharmaceuticals from September 2004 to December 2018, Miroslaw developed a quantitative proteomics workflow for human plasma analysis and various mass spectrometry techniques. Earlier experience includes roles at the Massachusetts Institute of Technology, where Miroslaw contributed to the generation of a heparan sulfate library and the examination of thrombotic disease genetics, as well as at Beth Israel Deaconess Medical Center, managing genetically engineered animals. Miroslaw holds a Bachelor of Science degree in Biomedical Laboratory and Clinical Sciences from Boston University.